Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

GLP-1 RA medications safe and very effective for treating obesity in adults without diabetes Data also shows some very promising options that are not yet FDA approved Abstract: https://www ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications, which suppress appetite and reduce food consumption. GLP-1 drugs, popular for weight loss, are expected to ...